Resverlogix Announces New Research Highlighting Apabetalone's Potential Benefits in Cardiovascular Disease, Heart Failure, and COVID-19
Calgary, Alberta--(Newsfile Corp. - March 2, 2023) - Resverlogix Corp. (TSX: RVX) ("Resverlogix") today announced the publication of two articles in peer-reviewed scientific journals. The first, entitled "Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation" by Fu et al., was published in International Immunopharmacology, and positions apabetalone as a variant-independent therapeutic for...
2023-03-02 7:15 AM EST
IIROC Trade Resumption - Resverlogix Corp.
Toronto, Ontario--(Newsfile Corp. - October 13, 2017) - Trading resumes in: Company: Resverlogix Corp.
2017-10-13 9:33 AM EDT
IIROC Trade Halt - Resverlogix Corp.
Toronto, Ontario--(Newsfile Corp. - October 13, 2017) - The following issues have been halted by IIROC: Company:
2017-10-13 9:22 AM EDT
IIROC Trade Resumption - Resverlogix Corp.
Toronto, Ontario--(Newsfile Corp. - July 25, 2017) - Trading resumes in: Company: Resverlogix Corp.
2017-07-25 9:07 AM EDT
CORRECTION FROM SOURCE: IIROC Trade Halt - Resverlogix Corp.
Toronto, Ontario--(Newsfile Corp. - July 25, 2017) - The following issues have been halted by IIROC: Company:
2017-07-25 8:03 AM EDT
IIROC Trade Halt - Resverlogix Corp.
Toronto, Ontario--(Newsfile Corp. - July 25, 2017) - The following issues have been halted by IIROC: Company:
2017-07-25 8:02 AM EDT
IIROC Trade Resumption - Resverlogix Corp.
Toronto, Ontario--(Newsfile Corp. - June 20, 2017) - Trading resumes in: Company: Resverlogix Corp.
2017-06-20 9:51 AM EDT
IIROC Trade Halt - Resverlogix Corp.
Toronto, Ontario--(Newsfile Corp. - June 20, 2017) - The following issues have been halted by IIROC: Company:
2017-06-20 8:11 AM EDT